Webster Bank N. A. Sells 2,014 Shares of Johnson & Johnson (NYSE:JNJ)

Webster Bank N. A. decreased its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 4.1% in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 46,718 shares of the company’s stock after selling 2,014 shares during the quarter. Webster Bank N. A.’s holdings in Johnson & Johnson were worth $6,756,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. IFS Advisors LLC increased its stake in Johnson & Johnson by 138.9% during the fourth quarter. IFS Advisors LLC now owns 172 shares of the company’s stock valued at $25,000 after acquiring an additional 100 shares during the period. Highline Wealth Partners LLC bought a new stake in shares of Johnson & Johnson during the third quarter valued at approximately $31,000. RPg Family Wealth Advisory LLC acquired a new position in shares of Johnson & Johnson in the third quarter valued at $35,000. Mowery & Schoenfeld Wealth Management LLC lifted its position in Johnson & Johnson by 58.7% in the third quarter. Mowery & Schoenfeld Wealth Management LLC now owns 246 shares of the company’s stock worth $40,000 after purchasing an additional 91 shares during the period. Finally, Activest Wealth Management acquired a new stake in Johnson & Johnson during the third quarter worth $40,000. Institutional investors and hedge funds own 69.55% of the company’s stock.

Johnson & Johnson Stock Up 0.6 %

NYSE JNJ opened at $151.27 on Thursday. The stock has a market capitalization of $364.20 billion, a P/E ratio of 22.75, a price-to-earnings-growth ratio of 2.45 and a beta of 0.51. Johnson & Johnson has a 52 week low of $140.68 and a 52 week high of $168.85. The company has a debt-to-equity ratio of 0.45, a quick ratio of 0.79 and a current ratio of 1.03. The stock has a fifty day moving average of $147.76 and a 200-day moving average of $156.13.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings data on Wednesday, January 22nd. The company reported $2.04 earnings per share for the quarter, topping the consensus estimate of $1.99 by $0.05. The firm had revenue of $22.52 billion during the quarter, compared to analysts’ expectations of $22.44 billion. Johnson & Johnson had a return on equity of 34.35% and a net margin of 18.20%. The company’s quarterly revenue was up 5.3% compared to the same quarter last year. During the same period in the previous year, the business posted $2.29 EPS. On average, equities research analysts forecast that Johnson & Johnson will post 10.56 EPS for the current year.

Johnson & Johnson Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, March 4th. Shareholders of record on Tuesday, February 18th will be issued a dividend of $1.24 per share. This represents a $4.96 dividend on an annualized basis and a yield of 3.28%. The ex-dividend date of this dividend is Tuesday, February 18th. Johnson & Johnson’s dividend payout ratio is presently 74.59%.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently commented on JNJ shares. Argus raised shares of Johnson & Johnson to a “strong-buy” rating in a report on Friday, January 24th. Stifel Nicolaus cut their price target on shares of Johnson & Johnson from $170.00 to $155.00 and set a “hold” rating for the company in a research note on Thursday, January 23rd. Wells Fargo & Company lowered their price objective on Johnson & Johnson from $166.00 to $152.00 and set an “equal weight” rating on the stock in a research note on Thursday, January 23rd. Royal Bank of Canada restated an “outperform” rating and set a $181.00 target price on shares of Johnson & Johnson in a research report on Thursday, January 23rd. Finally, Barclays upped their price target on Johnson & Johnson from $159.00 to $166.00 and gave the company an “equal weight” rating in a research report on Tuesday. Nine research analysts have rated the stock with a hold rating, eight have assigned a buy rating and two have given a strong buy rating to the company’s stock. According to MarketBeat.com, Johnson & Johnson presently has an average rating of “Moderate Buy” and a consensus price target of $170.44.

Insider Buying and Selling at Johnson & Johnson

In related news, Director Mark A. Weinberger acquired 1,000 shares of the company’s stock in a transaction that occurred on Thursday, December 12th. The stock was acquired at an average price of $147.22 per share, for a total transaction of $147,220.00. Following the completion of the acquisition, the director now owns 1,000 shares of the company’s stock, valued at $147,220. This trade represents a ∞ increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available at the SEC website. Corporate insiders own 0.16% of the company’s stock.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.